Goldman Sachs Starts Surface Oncology (SURF) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Boeing nears approval of 737 MAX anti-ice fix, paving way for deliveries
Evercore ISI Starts Surface Oncology (SURF) at Outperform
May 14, 2018 6:04 AM EDTEvercore ISI initiates coverage on Surface Oncology (NASDAQ: SURF) with a Outperform rating and a price target of $26.00.
Analyst Josh Schimmer said they believe SURF's approach of targeting the innate immune system as well is differentiated, and the company is developing a portfolio of... More
Cowen Starts Surface Oncology (SURF) at Outperform
May 14, 2018 5:38 AM EDTCowen initiates coverage on Surface Oncology (NASDAQ: SURF) with a Outperform rating.
Analyst Boris Peaker comments "Surface is developing several drugs against novel IO targets. Given the early stage nature of these targets, we believe that positive developments internally as well as... More
